Drug Price Trends for TUSSIN CF SEVERE MULTI-SYMPTOM

Average Pharmacy Cost for TUSSIN CF SEVERE MULTI-SYMPTOM

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
TUSSIN CF SEVERE MULTI-SYMPTOM	70000-0739-01	0.02556	ML	2026-06-17

Last updated: June 20, 2026

Tussin CF Severe Multi-Symptom Market Analysis and Price Projections (US)

Executive summary

Tussin CF Severe Multi-Symptom is an over-the-counter (OTC) combination cough-cold product. It is not typically priced or managed through patent-backed exclusivity the way prescription drugs are. As a result, “price projections” in this category are driven primarily by (1) OTC channel mix (mass, club, grocery, pharmacy), (2) private-label and store-brand substitution, (3) ingredient cost cycles for dextromethorphan, guaifenesin, and phenylephrine/pseudoephedrine-adjacent formulations (depending on product), (4) promotional intensity, and (5) state-level regulatory effects on phenylephrine access and stocking behavior. Without a verified NDC-level product specification (strengths and active ingredient list) and a specific pack configuration (count, liquid vs solid), any numeric price forecast would not be anchored to the actual SKU.

What is Tussin CF Severe Multi-Symptom’s active ingredient and strength profile?

Tussin CF Severe Multi-Symptom is an OTC multi-symptom cold/cough brand. In the Tussin CF family, “severe” labeling usually indicates a higher-strength combination versus basic variants, but the exact actives and mg per unit vary by formulation and packaging.

What matters for market sizing and pricing

• Active ingredient set and mg strength determine comparability to competing SKUs (generic actives, store brands).
• Pack format (liquid, capsules, tablets) drives per-treatment cost and compliance with retailer pricing “baskets.”
• NDC identity determines the specific item price drivers across retailers, wholesalers, and online pharmacies.

How large is the OTC cough-cold market that Tussin CF Severe Multi-Symptom participates in?

This product competes inside the broader US OTC cough and cold segment, which is seasonal and promotion-driven. The category’s unit demand correlates with winter respiratory seasons and weather patterns, and price variance is shaped by:

• pharmacy and mass retailer promotional calendars (BOGO, multi-buy discounts),
• shelf resets after cold snaps,
• online list price vs delivered promo price.

Market structure (channel dynamics)

• Mass and club: strongest price competition, highest store-brand share.
• Grocery: seasonal promotions and endcap volume.
• Drugstore: pharmacy programs and loyalty pricing.
• E-commerce: list price compression and frequent couponing.

Who are Tussin CF Severe Multi-Symptom’s key competitors?

Competitors generally fall into two groups:

1. Brand OTC multi-symptom cough/cold products with similar symptom claims.
2. Store-brand and generic active-ingredient combinations, priced below brands at mass and club.

Competitor set examples (category-level)

• Multi-symptom cough/cold liquids and tablets featuring dextromethorphan (cough), guaifenesin (chest congestion), and a decongestant (commonly phenylephrine in older formulations; depending on current product rules, alternative decongestant or formulation approaches may appear).
• Private-label “maximum strength” versions with comparable actives and symptom positioning.

Which patents protect Tussin CF Severe Multi-Symptom and how does IP affect pricing?

As an OTC combination product, Tussin CF Severe Multi-Symptom pricing is typically not constrained by active exclusivity in the same way prescription branded products are. Competitive pricing pressure comes from:

• entry of multiple manufacturers using the same well-established actives,
• private-label versions using the same ingredients at equivalent strengths,
• formulation process IP that rarely sustains broad retail pricing power.

How strong is the patent estate and what does that imply for retail price power?

For OTC cough/cold combinations, patent estates tend to be narrower (for specific formulation/process or packaging) and do not reliably prevent generic or store-brand substitution. When substitution is easy, brand pricing power is limited to:

• temporary retailer promotions,
• pack-size-specific advantages,
• brand equity and shelf availability.

What is the Orange Book status of Tussin CF Severe Multi-Symptom?

Tussin CF Severe Multi-Symptom is OTC. The Orange Book generally covers approved prescription drugs with FDA-approved drug applications and related patents. OTC products are often not the basis for Orange Book exclusivity listings. That means Orange Book status typically does not explain price outcomes for this OTC category.

How does FDA OTC regulation affect product availability and pricing?

For OTC cough/cold combinations, FDA impacts pricing mostly via:

• monograph compliance and labeling requirements,
• ingredient rule changes and enforcement priorities,
• retailer stocking decisions when ingredient formulations or labeling become constrained.

These mechanisms change supply and product mix over time, but do not usually create long-lived brand pricing barriers.

What is the pricing baseline for Tussin CF Severe Multi-Symptom (per unit and per dose)?

A valid price projection requires:

• the exact NDC,
• the current retail price at a defined set of retailers (mass, drugstore, e-commerce),
• the pack size and dosing units.

Without those inputs, any numeric pricing baseline would mix non-comparable SKUs (wrong strength, wrong form factor, wrong pack size), producing invalid forecasts.

Price projections: what drives upward vs downward movement in OTC multi-symptom cough/cold SKUs?

Even without a specific SKU price feed, directionally the category moves due to:

Upward pressures

• ingredient cost increases for key actives,
• freight and packaging inflation,
• supply disruptions after regulatory or manufacturing shifts,
• reduced private-label availability during peak season.

Downward pressures

• increased store-brand substitution,
• competitive promo intensity (coupon cycles, multi-buy discounts),
• normalization after cold-season peaks,
• retailer margin optimization (price cuts to protect share).

When do OTC price changes typically occur for cough/cold products?

Seasonality is the dominant timeline feature:

• Early season: brands and retailers raise or maintain list prices while inventory builds.
• Peak season: price volatility increases due to promotions and high demand pull-through.
• Late season: promotions intensify to clear inventory; delivered prices compress.

A robust projection would map price by:

• month,
• retailer category (mass vs pharmacy),
• promotion week vs non-promotion week.

What generic entry risks exist for Tussin CF Severe Multi-Symptom?

For OTC combinations with established actives, “generic entry risk” manifests as:

• additional manufacturers producing the same active combination,
• store-brand expansions that undercut brand pricing,
• re-packaging into equivalent strengths that bypass consumer brand preference.

This tends to reduce sustained price increases and keeps brand price resilience reliant on promotions and availability.

How does Tussin CF Severe Multi-Symptom compare with store brand and private label on price per treatment?

In OTC cough/cold, store brands typically price below branded products on:

• per dose,
• per unit fluid ounce or tablet count,
• “value pack” equivalents.

If Tussin CF’s actives and strengths match competitor compositions, the brand’s economic advantage usually narrows to:

• consumer habit,
• retailer shelf placement,
• short-lived promotions that align price-per-dose with private label thresholds.

What manufacturing and distribution/IP barriers could limit price erosion?

Barriers in OTC combinations are usually lower than in prescription monopolies. Potential constraints that can slow price erosion include:

• limited contract manufacturing capacity for a specific formulation,
• bottlenecks in sourcing particular actives,
• retailer-specific exclusivity for certain pack SKUs (contracted shelf agreements).

Key scenario-based price projection framework for the next 6–18 months

A defensible projection would use SKU-level pricing and promo calendar data. In absence of NDC and pack configuration, the scenario framework is:

Base-case

• Mild real-price compression during peak season through promotions
• List price stability post-season with occasional retailer discounts

Downside

• Private-label share gains intensify
• Competitive promos widen, driving lower average selling prices
• Ingredient cost increases are not fully passed through

Upside

• Ingredient shortages or supply constraints reduce promo frequency
• Retailers maintain shelf price to preserve margins
• Brand promotion intensity moderates

Market actionability: where to pressure-test pricing

Even without numeric forecasts, the highest-leverage tests are:

• Retailer-by-retailer price tracking (mass vs pharmacy vs e-commerce)
• Promo elasticity: average selling price in promo weeks vs non-promo weeks
• Pack-size substitution: whether consumers switch to smaller/cheaper packs
• Store-brand cross-shopping: whether equivalent “maximum strength” substitutes capture share

Key Takeaways

• Tussin CF Severe Multi-Symptom is an OTC multi-symptom cough/cold product; pricing dynamics are driven by retailer promotion intensity and store-brand substitution more than by patent exclusivity.
• Any numeric price projection requires SKU-level identification (NDC, strength, and pack size); otherwise forecasts are not comparable and would not be decision-grade.
• Over 6–18 months, the category typically trends toward list-price stability with promo-driven average price compression, strongest during peak season.

FAQs

1. How do I compare Tussin CF Severe Multi-Symptom pricing across retailers without mixing different NDCs?
2. What are the typical promo patterns for OTC cough and cold multi-symptom products in the US?
3. Does retailer placement (endcap vs shelf) materially change average selling price for cough/cold OTC brands?
4. How does store-brand “maximum strength” substitution usually affect branded OTC market share?
5. What ingredient regulatory changes most often reshape OTC availability and pricing for cough/cold combination products?

References

No sources were cited.